Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted loss per share gives the effect to all dilutive potential common shares outstanding during the period, including stock options, warrants and convertible instruments. Diluted net loss per share excludes all potentially issuable shares if their effect is anti-dilutive. Because the effect of the Company’s dilutive securities is anti-dilutive, diluted net loss per share is the same as basic loss per share for the periods presented.
The above information was disclosed in a filing to the SEC. To see the filing, click here.
To receive a free e-mail notification whenever TransBiotec, Inc. makes a similar move, sign up!
Other recent filings from the company include the following:
TransBiotec, Inc. director just picked up 11,765 shares - June 21, 2022
TransBiotec, Inc. director just declared ownership of no shares of TransBiotec, Inc. - June 15, 2022
TransBiotec, Inc.'s CFO just declared ownership of no shares of TransBiotec, Inc. - June 13, 2022
TransBiotec, Inc.'s CFO just picked up 11,765 shares - June 13, 2022